While researching another topic, I came across this from 1998, Effects of vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. This is logical (just need the RIGHT vaccine) from observations made in my last post.
” Significant improvement was seen in seven of the 15 CPRS items in the vaccine group when pretreatment values were compared to post-treatment values. In CPRS <<fatiguability>>, there were significant intergroup differences, and in CPRS <<pain>> intergroup differences bordered on significance…. In a follow-up study of 23 patients, thevaccine treatment was continued for 2-6 years. Fifty percent were rehabilitated successfully and resumed half-time or full-time work.”
This was followed up with a 2002 study. ” The treatment was well tolerated. Intention-to-treat analysis showed 32/49 (65%) responders in the SB(vaccine) group compared to 9/49 (18%) in the placebo group (P<0.001). … An increase in CPRS symptoms at withdrawal was noted in the SB group. In conclusion, treatment with staphylococcus toxoid injections over 6 months led to significant improvement in patients with FM and CFS. Maintenance treatment is required to prevent relapse.” 
“One hundred and sixty patients with Fibromyalgia and Chronic Fatigue Syndrome, who were on a continuous treatment with a Staphylococcus vaccine, were followed during one year with repeated consultation visits…. showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.”[2006 article in Journal of Chronic Fatigue]
Discussion from 2010 on Phoenix Rising.
BENEFITS OF VACCINE FOR ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS:
- Polyvalent vaccine targets antibiotic resistant strains of S. aureus
- Provides protection against the most common strains of S. aureus
- Targets toxins secreted from S. aureus
- Mechanism of action targets surface proteins
The vaccine is available for veterinary use.
It is worth while for a researcher to explore producing a series of vaccines for overgrowth species/strains in CFS/FM. It may be possible to do this with a similar method as was used in the 1930’s (i.e. not high tech). The 50% success rate seen in multiple studies is in line with a microbiome dysfunction that is multiple species — thus any single item will likely only be partially effective.
Recent literature and reports on the vaccine itself (National Institute of….):
- Where does a Staphylococcus aureus vaccine stand? 
- Overcoming Challenges in Staphylococcus aureus Vaccine Development [June 2013]
Fast Track Clinical Trials (not for CFS):